Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement (“SPA”) pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited (“Charme”), a pan-European private equity firm, for a cash purchase price of EUR 8,717,906.80.

Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trials

CENTOGENE received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq.

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

CENTOGENE today announced the voting results of the Company’s 2024 Annual General Meeting. Shareholders voted in favor of all proposals.

Reported Full Year 2023 total revenues

Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research; Companies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

CENTOGENE Receives Nasdaq Non-Compliance Notice April 2024

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of the Rare Disease, Human Pre-TCRα Deficiency

CENTOGENE Explores Strategic Alternatives

CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development